The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance

Eugenia Opolka-Hoffmann(Roche (Switzerland)), Roland F. Staack(Roche Pharma AG (Germany)), Robin Kieferle(Roche Pharma AG (Germany)), Martin Lechmann(Roche (Switzerland)), Gregor Jordan(Roche Pharma AG (Germany)), Michael B. Otteneder(Roche (Switzerland)), Gerhard Winter(University of New England)
mAbs
January 1, 2021
10.1080/19420862.2021.1995929
Cited by 27

Related Papers

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170
Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery
|European Journal of Pharmaceutics and Biopharmaceutics|2010|151
T– and B–Cell Responses to Different Hepatitis C Virus Antigens in Patients With Chronic Hepatitis C Infection and in Healthy Anti– Hepatitis C Virus—Positive Blood Donors Without Viremi
|Hepatology|1996|149
Immunopurification and Mass Spectrometric Quantification of the Active Form of a Chimeric Therapeutic Antibody in Human Serum
|Analytical Chemistry|2008|144
Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)
|International Journal of Cancer|2007|136